NCT07421258Completed
A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting
Treat-to-Target and Disease Modification in Inflammatory Bowel Disease: A Worldwide Routine Practice Study
Source: ClinicalTrials.gov · Last updated 5 Oct 2026
Brief summary (registry, in English)
Inflammatory Bowel Disease (IBD), encompassing Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic, relapsing, and often disabling condition characterized by inflammation of the gastrointestinal tract. A treat-to-target strategy (T2T) is recommended by international guidelines to optimize long-term outcomes in IBD. The purpose of this study is to describe the real-life implementation of T2T in IBD worldwide and the association between using a T2T strategy and disease outcomes. This is a multi-country, observational, retrospective (non-interventional) study with a cross-sectional component based upon a sample of adult participants with IBD. All objectives will be assessed for IBD and then for CD/UC separately. Primary and secondary objectives will be assessed for the overall population over the 24 months study period. As this is an observational study, enrolled participants will be managed and followed up according to the standard practice. Retrospective chart review over the 24-months from date of inclusion will allow us to collect the variables of interest by using an e-CRF. There will be no additional burden for participants in this trial. Study visits will not be required as this is a retrospective chart review.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1638 (actual)
- First submitted
- 22 Sept 2025
- Start date
- 9 Feb 2026
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- AbbVie
- Diseases
- Crohn's disease, Ulcerative colitis
- NCT number
- NCT07421258
What you commit to
- Study type: Observational
- Participants enrolled: 1638
- From 9 Feb 2026 to the primary completion date, 1 Sept 2026
- 5 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants who had received treatment with any investigational drug/device/intervention over the past 24 months prior to the enrolment
Other illness
- History of proctocolectomy
Other
- Participants under legal protection
Who the study is looking for
- Adult male and female participants (\>= 18 years old) at the inclusion date who present within the usual course of care
- Participants able to provide voluntary informed consent prior to any study data collection
- Participant diagnosed with Crohn's Disease (CD) or Ulcerative Colitis (UC) for at least 24 months at the inclusion date
- With \>= 24 months of available medical records from the inclusion date
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chongqing General Hospital /ID# 282777 Coordinator of this site? Confirm its status | Chongqing | China | Unknown status |
| CHU Amiens-Picardie Site Sud /ID# 280263 Coordinator of this site? Confirm its status | Amiens | France | Unknown status |
| Centre Hospitalier Universitaire de Nimes - Hopital Universitaire Caremeau /ID# 282775 Coordinator of this site? Confirm its status | Nîmes | France | Unknown status |
| Centre Hospitalier Regional Universitaire de Nancy - Hopitaux de Brabois /ID# 280265 Coordinator of this site? Confirm its status | Vandœuvre-lès-Nancy | France | Unknown status |
| Kitasato University Kitasato Institute Hospital /ID# 282803 Coordinator of this site? Confirm its status | Minato-ku | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.